Free Fatty Acid Receptors
FFAR1 (GPR40) is a G protein-coupled receptor for medium and long chain saturated and unsaturated fatty acids. It plays a role in glucose homeostasis, insulin secretion and bone homeostasis etc.
Products Related to Free Fatty Acid Receptors(16)
- GC11467AS 2034178CAS: 1030846-42-4Purity: >98%
AS 2034178, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement.
- GC16176GSK 137647CAS: 349085-82-1Purity: >98.00%
GSK 137647 (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively.
- GC50333AMG 837 hemicalcium saltCAS: 1291087-14-3Purity: >98%
AMG 837 hemicalcium salt is a potent, orally bioavailable and partial agonist of GPR40/FFA1.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC10373 | MEDICA 16 | 87272-20-6 | >98% | |
Free fatty acid 1 (FFA1/GPR40) receptor agonist | ||||
| GC10922 | TUG 424 | 1082058-99-8 | >98.00% | |
FFA1 (GPR40) agonist | ||||
| GC11467 | AS 2034178 | 1030846-42-4 | >98% | |
AS 2034178, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. | ||||
| GC16176 | GSK 137647 | 349085-82-1 | >98.00% | |
GSK 137647 (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. | ||||
| GC17149 | 4-CMTB | 300851-67-6 | >99.00% | |
4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator. | ||||
| GC17753 | AH 7614 | 6326-06-3 | >99.50% | |
AH 7614 is a selective free fatty acid receptor 4 (FFA4/GPR120) antagonist. AH 7614 exhibits pIC 50 values of 7.1, 8.1, and 8.1 for human, mouse, and rat FFA4, respectively. | ||||
| GC11434 | GSK1292263 | 1032823-75-8 | >99.00% | |
Novel GPR119 agonist | ||||
| GC12401 | GW9508 | 885101-89-3 | >98.00% | |
FFA1/GPR40 agonist,potent and selective | ||||
| GC14027 | GW-1100 | 306974-70-9 | >98% | |
A selective GPR40 antagonist | ||||
| GC16054 | TUG-770 | 1402601-82-4 | >99.50% | |
An agonist of FFA1/GPR40 | ||||
| GC16555 | TAK-875 | 1000413-72-8 | >98.50% | |
TAK-875 is a potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist with an EC 50 value of 0.014μM for human GPR40. | ||||
| GC50293 | CATPB | 1322598-09-3 | >98.00% | |
FFA2 (GPR43) inverse agonist | ||||
| GC50313 | ZQ 16 | 376616-73-8 | >98% | |
Selective GPR84 agonist | ||||
| GC50333 | AMG 837 hemicalcium salt | 1291087-14-3 | >98% | |
AMG 837 hemicalcium salt is a potent, orally bioavailable and partial agonist of GPR40/FFA1. | ||||
| GC50578 | AZ 1729 | 2016864-46-1 | >98% | |
FFA2 allosteric agonist; displays bias for the Gi signaling pathway | ||||
| GC50662 | DL 175 | 2487253-25-6 | >98.00% | |
